HOME >> BIOLOGY >> NEWS
Cancer related gene p53 not regulated as indicated by previous tissue culture research

The cellular cascade of molecular signals that instructs cells with fatally damaged DNA to self-destruct pivots on the p53 tumor suppressor gene. If p53 is inactivated, as it is in over half of all human cancers, checks and balances on cell growth fail to operate, and body cells start to accumulate mutations, which ultimately may lead to cancer. Not surprisingly, the regulation of this vital safeguard has been studied in great detail for many years but mainly in tissue culture, or in vitro, models.

A new mouse model, created by scientists at the Salk Institute for Biological Studies, suggests that what researchers have learned about the regulation of p53 activity from in vitro studies may not be relevant to living, breathing organisms. The Salk scientists' findings are published in this week's online early edition of the journal Proceedings of the National Academy of Sciences.

Until now, scientists had assumed, based on studies in cultured cells, that p53 had to be modified by attaching chemical groups to specific sites on the protein to function normally in the body. The new research indicates that these modifications are not necessary to activate p53 under conditions of stress or to prevent p53 from throwing a wrench into the cell cycle machinery, when nothing is wrong.

"The chemical modifications of the p53 protein that we thought were essential for its normal function may just fine-tune the activity of the protein under physiological conditions in a living organism, but they are not essential," explains lead investigator professor Geoffrey M. Wahl. "This new study focuses our attention on the network of regulators of p53 and how they are regulated."

"This study caused a big shift in how we think about p53," explains Salk scientist and first author Kurt Krummel. "You have to look at all interacting partners because after all, modifications of p53 itself might not be so important as modifications of negative regulators and co-a
'"/>

Contact: Cathy Yarbrough
yarbrough@salk.edu
858-452-8051
Salk Institute
27-Jun-2005


Page: 1 2 3

Related biology news :

1. Journalists can register now for ECCO 14 -- the European Cancer Conference
2. Cancer cures could work for canines and humans
3. The Cancer Genome Atlas awards funds for technology development
4. Cancer research specialist and HSPH professor awarded Medal of Honor from WHO cancer agency
5. Cancer stem cells similar to normal stem cells can thwart anti-cancer agents
6. Cancer stem cells can go it alone
7. Cancer drug enhances long-term memory
8. Cancer cells reprogram energy needs to grow and spread, study suggests
9. Cancer scientists create human leukemia process to map how disease begins, progresses
10. Cancer tip -- Nanoparticles can damage DNA, increase cancer risk
11. Other highlights from the April 18 Journal of the National Cancer Institute

Post Your Comments:
(Date:5/21/2013)... the world,s largest scientific society, invites news media ... September 8-12, 2013, in Indianapolis, Ind. It will ... at area hotels. , With more than 7,100 ... from astronomy to zoology ― the meeting ... rich assortment of spot news and feature possibilities. ...
(Date:5/21/2013)... which alter the way genes function without changing ... in the blood of pregnant women during any ... depression in the weeks after giving birth, and ... , The findings of the small study involving ... journal Molecular Psychiatry . , "Postpartum depression ...
(Date:5/20/2013)... suggests that a compound abundant in the Mediterranean diet ... , By altering a very specific step in gene ... cells that die as scheduled. , One way that ... would cause them to die on a regular cycle ... cells, led by Ohio State University researchers, found that ...
Breaking Biology News(10 mins):Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3
(Date:5/21/2013)... May 21, 2013 According to ... ( http://www.transparencymarketresearch.com ) "Biochip Products and Services Market (Microarrays, ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the ... and is expected to grow at a CAGR of ... value of USD 4.7 billion in 2018. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. ... study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal ... expressing the HER2 oncoprotein," will be presented at ... of Clinical Oncology during the Developmental Therapeutics - ... at 4:15 – 4:30 PM.  The presentation will ...
(Date:5/21/2013)... Revolutionary Science, the manufacturer of the ... today that they have expanded their colony counter product ... IntelliCount, InCount and ImpressCount. These affordable colony counters ... in food microbiology and pharmaceutical manufacturing. , The previously ... A bright white enclosure with jet black accents represent ...
(Date:5/21/2013)... MA (PRWEB) May 21, 2013 Possible mold ... And so, according to a report from eagletribune.com posted May ... mold. In case the result is positive, My Cleaning Products ... using harmful chemical ingredients. , It was said in the ... re-infestation in the campus sparked after a first-grade classroom ...
Breaking Biology Technology:The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 3
Cached News: